News Sentiment

CLRB sentiment intelligence

Cellectar Biosciences Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 54 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.51 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-11.0% over one week, -10.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Cellectar Biosciences (CLRB) Q1 2026 earnings summary

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -11.0% Price reacting lower
Trend fit Trend inactive -10.0% over four weeks
Fair value -93.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 43
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
Market source 7
TradingView 4
GlobeNewswire 4
Quartr 3
Investing.com 2
MarketBeat 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 20
Regulatory and legal 5
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 54
Quartr Direct company coverage

Cellectar Biosciences (CLRB) Q1 2026 earnings summary

Cellectar Biosciences reported a transformational Q1 2026, driven by positive 12-month data from the CLOVER-WaM study for iopofosine I-131, which supports plans for accelerated FDA approval. The company also secured up to $140 million in financing and dosed the first patients in

Tone
Positive 74/100
Event
Earnings
Published
22 Jul 2026 12:12
Source
Quartr
Quartr Direct company coverage

Cellectar Biosciences (CLRB) Proxy filing Summary

Cellectar Biosciences (CLRB) has scheduled its Annual Meeting for July 7, 2026, to be held virtually, with stockholders of record as of May 19, 2026, eligible to vote. Key proposals include the election of two Class III directors, an increase in shares for the 2021 Stock Incentiv

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 12:12
Source
Quartr
Quartr Direct company coverage

Cellectar Biosciences (CLRB) Registration filing Summary

Cellectar Biosciences (CLRB), a late-stage clinical biopharmaceutical company, has filed a registration summary detailing its business model, financial performance, and capital allocation. The company, which focuses on developing cancer treatments using a proprietary phospholipid

Tone
Neutral 50/100
Event
Market update
Published
22 Jul 2026 12:12
Source
Quartr
Bitget Direct company coverage

Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia

Cellectar BioSciences has published a corporate presentation detailing its phospholipid drug conjugate radiotherapy pipeline, highlighting iopofosine I-131 for Waldenström macroglobulinemia. The company plans to seek US accelerated approval for iopofosine I-131 in the first half

Tone
Positive 77/100
Event
Regulatory and legal
Published
21 Jul 2026 19:10
Source
Bitget
Sahm Direct company coverage

Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers

Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study of iopofosine I 131 in combination with low-dose dexamethasone for relapsed/refractory multiple myeloma in the journal *Cancers*. The study showed a favorable safety profile with man

Tone
Positive 70/100
Event
Earnings
Published
17 Jul 2026 05:42
Source
Sahm
Investing.com Direct company coverage

Cellectar publishes phase 1 data on multiple myeloma treatment

Cellectar Biosciences Inc. announced positive Phase 1 study results for iopofosine I 131 combined with low-dose dexamethasone in relapsed/refractory multiple myeloma patients. The study showed manageable toxicity, encouraging disease control, and antitumor activity, with an overa

Tone
Positive 72/100
Event
Earnings
Published
15 Jul 2026 12:12
Source
Investing.com
Stock Titan Direct company coverage

Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better

Cellectar Biosciences announced the publication of Phase 1 study results for iopofosine I 131 with low-dose dexamethasone in heavily pretreated relapsed/refractory multiple myeloma patients in the peer-reviewed journal Cancers. The study showed that 84.6% of 26 evaluable patients

Tone
Positive 91/100
Event
Earnings
Published
15 Jul 2026 11:12
Source
Stock Titan
Minichart Direct company coverage

Cellectar Biosciences, Inc. Files Form 8-K: Updated Stock Incentive Plan and Corporate Details for 2026

Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced key developments from its 2026 Annual Meeting of Stockholders, including the approval of a material amendment to its 2021 Stock Incentive Plan, increasing shares reserved for issuance by 2,000,000. Shareholders also approved ex

Tone
Neutral 50/100
Event
Regulatory and legal
Published
11 Jul 2026 01:20
Source
Minichart
Investing.com Canada Direct company coverage

Form 4 Cellectar Biosciences Inc For: 10 July By Investing.com

This article reports on a Form 4 filing for Cellectar Biosciences Inc (CLRB) on July 10, 2026. Form 4 filings disclose transactions by company insiders, indicating purchases or sales of company stock. The article provides the company name and filing date but no further details on

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 01:09
Source
Investing.com Canada
Stock Titan Direct company coverage

Cellectar Biosciences (NASDAQ: CLRB) awards 15,000 stock options to consultant

Cellectar Biosciences (NASDAQ: CLRB) has awarded 15,000 stock options to consultant Loren Stefan. These options have an exercise price of $2.6900 per share and will expire on July 8, 2036. The award vests in full on July 8, 2027, provided Stefan continues his service until that d

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 01:06
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar Biosciences (NASDAQ: CLRB) holders approve more stock awards and large warrant exercise

Cellectar Biosciences (NASDAQ: CLRB) stockholders approved several key proposals at their 2026 Annual Meeting, including the election of Class III directors, an increase of 2,000,000 shares for their 2021 Stock Incentive Plan, and the ratification of Deloitte & Touche LLP as thei

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar (CLRB) director receives 25,000 stock options at $2.70 strike

Cellectar Biosciences director Frederick W. Driscoll was granted 25,000 stock options with an exercise price of $2.70 per share. These options will vest in full on July 7, 2027, subject to his continued service, and are set to expire on July 7, 2036. This transaction increased hi

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 13:39
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar Biosciences (CLRB) director awarded 25,000 options at $2.70 strike

Cellectar Biosciences director John Neis was granted 25,000 stock options with an exercise price of $2.70 per share, expiring on July 7, 2036. The options will fully vest on July 7, 2027, provided Neis continues his service to the company. This constitutes a compensation award ra

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 02:12
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar (CLRB) awards director Andrew Gu 25,000 options

Cellectar Biosciences director Andrew Gu was granted 25,000 stock options as equity compensation on July 7, 2026. These options have an exercise price of $2.70 per share and an expiration date of July 7, 2036. The options will fully vest on July 7, 2027, provided he continues his

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 02:12
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar Biosciences (CLRB) director receives grant of 25,000 stock options

Cellectar Biosciences director Asher Chanan-Khan was granted 25,000 stock options with an exercise price of $2.70 per share, expiring on July 7, 2036. The options will vest in full on July 7, 2027, contingent on his continued service to the company. This transaction is classified

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 02:10
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar (CLRB) CFO awarded 92,000 stock options at $3.14 strike price

Cellectar Biosciences CFO Chad J. Kolean has been awarded 92,000 stock options with a strike price of $3.14 per share, contingent on stockholder approval of the amended 2021 Stock Incentive Plan, which occurred on July 7, 2026. These options will vest over a three-year period, wi

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 02:10
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Cellectar Biosciences Inc For: 8 July By Investing.com

This article provides a Form 4 filing for Cellectar Biosciences Inc (CLRB) on July 8. It indicates a minor positive change in the stock price (+0.18%) and was published by Investing.com. The content primarily serves as an announcement for the regulatory filing.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 02:08
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Cellectar Biosciences (CLRB) CEO awarded 250,000 stock options

Cellectar Biosciences' President & CEO, James V. Caruso, was granted 250,000 stock options at an exercise price of $3.14 per share. This grant was contingent on stockholder approval of the amended 2021 Stock Incentive Plan, which occurred on July 7, 2026. The options will vest ov

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 01:41
Source
Stock Titan
Stock Titan Direct company coverage

Cellectar Biosciences (CLRB) director granted 37,500 stock options

Douglas J. Swirsky, a director at Cellectar Biosciences (CLRB), was granted 37,500 stock options with an exercise price of $2.70 per share. These options are a compensation award, not an open-market transaction, and will fully vest on July 7, 2027, provided he continues his servi

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 01:41
Source
Stock Titan
Stock Titan Direct company coverage

Consultant for Cellectar (NASDAQ: CLRB) receives grant of 15,000 stock options

Cellectar Biosciences, Inc. consultant Loren Stefan was granted 15,000 stock options with an exercise price of $2.68 per share, which will vest fully on July 8, 2027, provided continued service. These options expire on July 8, 2036. This transaction is an insider grant, not a mar

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 01:04
Source
Stock Titan
Finviz Direct company coverage

CLRB - Cellectar Biosciences Inc Options

This article provides a detailed financial overview of Cellectar Biosciences Inc (CLRB), including its last closing price, dollar and percentage changes, and various financial metrics such as market cap, income, sales, and employee count. It also covers performance indicators lik

Tone
Negative 41/100
Event
Market update
Published
03 Jul 2026 11:40
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBIT forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB

The document displays the enterprise value to EBIT forward for Cellectar Biosciences, Inc. (NASDAQ: CLRB) on TradingView. It provides market data, financial figures, and other company-specific information.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

Cellectar Biosciences, Inc. Actuals & Estimates (NASDAQ:CLRB)

This article provides an overview of Cellectar Biosciences, Inc. (NASDAQ: CLRB) stock, including its current price, market capitalization, and historical performance. It also covers analyst forecasts, past earnings reports, and information on upcoming earnings dates, indicating t

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Cellectar Biosciences, Inc. – NASDAQ:CLRB

The article focuses on the enterprise value to revenue forward of Cellectar Biosciences, Inc. (NASDAQ: CLRB). It provides a snapshot of the company's financial overview within the health technology and pharmaceuticals sector on the Nasdaq Stock Market.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:10
Source
TradingView